AVDL Overview

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Wall Street analysts forecast AVDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVDL is21.67 USD with a low forecast of 20.00 USD and a high forecast of 22.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Avadel Pharmaceuticals PLC revenue for the last quarter amounts to 77.47M USD, increased 54.86

Avadel Pharmaceuticals PLC. EPS for the last quarter amounts to 0.00 USD, decreased -100.00

Avadel Pharmaceuticals PLC (AVDL) has 188 emplpoyees as of March 12 2026.

Today AVDL has the market capitalization of 1.38B USD.